natgillin/translations-raw huggingface dataset:
A pharmaceutical preparation for use in treating an individual having preeclampsia characterized by hypertension, proteinuria, or a combination thereof, wherein the pharmaceutical preparation comprises a therapeutically effective amount of digestive enzymes, wherein the digestive enzymes comprise amylase, lipase, and protease. 
Farmaceutski pripravak za uporabu u liječenju osobe koja ima preeklampsiju karakteriziranu hipertenzijom, proteinurijom ili njihovom kombinacijom, pri čemu farmaceutski pripravak sadrži terapijski učinkovitu količinu probavnih enzima, pri čemu probavni enzimi sadrže amilaze, lipaze i proteaze.
and R5 being each, independently of one another, a hydrogen atom, a (C1-C6)alkyl group or a heterocycloalkyl group; or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring; is a hydrogen atom, a halogen atom or a (C1-C6)alkyl group; 
i R5 su svaki, međusobno neovisno, vodikov atom, (C1-C6)alkil skupina ili heterocikloalkil skupina; ili osim toga R4 i R5 zajedno tvore, s dušikovim atomom koji ih nosi, 4- do 7-člani prsten; je vodikov atom, atom halogena ili (C1-C6)alkil skupina;
A compound according to Claim 1 or 2, wherein: R is a phenyl, pyridinyl or pyrazolyl group substituted with R1, R'1, R2 and R3; 
Spoj prema zahtjevu 1 ili 2, naznačen time da: R je fenil, piridinil ili pirazolil skupina supstituirana s R1, R'1, R2 i R3;
a hydrogen or chlorine atom or a methyl, cyclopropyl or methoxy group; 
atoma vodika ili klora ili metil, ciklopropil ili metoksi skupine;
or else R4 and R5 together form, with the nitrogen atom bearing them, a 4- to 7-membered ring; and 
ili osim toga R4 i R5 zajedno tvore, s dušikovim atomom koji ih nosi, 4- do 7-člani prsten; i
or else R4 and R5 together form, with the nitrogen atom bearing them, a 4- to 7-membered ring; and is a hydrogen atom, a halogen atom or a (C1-C6)alkyl group; 
ili osim toga R4 i R5 zajedno tvore, s dušikovim atomom koji ih nosi, 4- do 7-člani prsten; i je vodikov atom, atom halogena ili (C1-C6)alkil skupina;
wherein when R corresponds to formula (A), R2 and R3 can together form an azepinyl or oxazepinyl ring fused with the phenyl bearing them, this azepinyl or oxazepinyl being optionally substituted with one or more substituents selected, independently in each instance, from: an oxo group and a (C1-C6)alkyl group; or a pharmaceutically acceptable salt thereof. 
pri čemu kada R odgovara formuli (A), R2 i R3 mogu zajedno tvoriti azepinil ili oksazepinil prsten kondenziran s fenilom koji ih nosi, navedeni azepinil ili oksazepinil su proizvoljno supstituirani s jednim ili više supstituenata koji su odabrani, svaki puta neovisno, od: okso skupine i (C1-C6)alkil skupine; ili njegova farmaceutski prihvatljiva sol.
R'4 is a hydrogen atom or a (C1-C6)alkyl group or aryl group, said (C1-C6)alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group; n is 1 or 2; is a halo(C1-C6)alkyl group; 
R'4 je vodikov atom ili (C1-C6)alkil skupina ili aril skupina, navedene (C1-C6)alkil i aril skupine su proizvoljno supstituirane s atomom halogena ili NH2 ili OH skupinom; n je 1 ili 2; je halo(C1-C6)alkil skupina;
R'1 is a hydrogen atom or an isopropyloxy group; is selected from: 
R'1 je vodikov atom ili izopropiloksi skupina; je odabran od:
a hydrogen or chlorine atom or a methyl, cyclopropyl or methoxy group; 
vodika ili atoma klora ili metil, ciklopropil ili metoksi skupine;
said (C1-C6)alkyl group being optionally substituted with a halogen atom or a (C1-C6)alkoxy, heterocycloalkyl, NH2 or OH group; and wherein: and R5 each is, independently of one another, a hydrogen atom, a (C1-C6)alkyl group or a heterocycloalkyl group; 
navedena (C1-C6)alkil skupina je proizvoljno supstituirana s atomom halogena ili (C1-C6)alkoksi, heterocikloalkil, NH2 ili OH skupinom; i pri čemu: i R5 je svaki, međusobno neovisno, vodikov atom, (C1-C6)alkil skupina ili heterocikloalkil skupina;
R is selected from the following groups: 
R je odabran od slijedećih skupina: [image] [image]
R'1 is a hydrogen atom or an isopropyloxy group; 
R'1 je vodikov atom ili izopropiloksi skupina;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4-to 7-membered ring; is a hydrogen atom, a halogen atom or a (C1-C6)alkyl group; 
ili osim toga R4 i R5 zajedno tvore, s dušikovim atomom koji ih nosi, 4- do 7-člani prsten; je vodikov atom, atom halogena ili (C1-C6)alkil skupina;
is a halo(C1-C6)alkyl group; or a pharmaceutically acceptable salt thereof. 
je halo(C1-C6)alkil skupina; ili njegova farmaceutski prihvatljiva sol.
is a hydrogen or fluorine atom or a methyl; 
je vodik ili atom fluora ili metil;
A compound according to any one of Claims 1 to 11, wherein it is selected from the following compounds: 
Spoj prema bilo kojem od zahtjeva 1 do 11, naznačen time da je odabran iz skupa koji čine slijedeći spojevi:
these heterocycloalkyl, heterocycloalkyl-CH2- and heteroaryl groups being optionally substituted with one or several substituents selected, independently in each instance, from: (C1-C6)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkoxy, heterocycloalkyl, carboxy(C1-C6)alkyl, NR4R5 and OR4; 
navedene skupine heterocikloalkil, heterocikloalkil-CH2- i heteroaril su proizvoljno supstituirane s jednim ili nekoliko supstituenata koji su odabrani, svaki puta neovisno, iz skupa koji čine: (C1-C6)alkil, (C3-C7)cikloalkil, (C1-C6)alkoksi, heterocikloalkil, karboksi(C1-C6)alkil, NR4R5 i OR4;
said (C1-C6)alkyl group being optionally substituted with a halogen atom or a (C1-C6)alkoxy, heterocycloalkyl, NH2 or OH group; and 
navedena (C1-C6)alkil skupina je proizvoljno supstituirana s atomom halogena ili sa (C1-C6)alkoksi, heterocikloalkil, NH2 ili OH skupinom; i
an NRaRb group, where Ra and Rb are, independently of one another: . 
skupine NRaRb, gdje Ra i Rb su, međusobno neovisno: .
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring; 
ili osim toga R4 i R5 zajedno tvore, s dušikovim atomom koji ih nosi, 4- do 7-člani prsten;
then step a) is followed: 
tada se slijedi korak a):
either by a step of treating the mixture obtained with an aqueous ammonia solution so as to obtain the compounds of formula (I) wherein R6 is -CONH2; 
ili s korakom obrade nastale smjese s vodenom otopinom amonijaka tako da se dobiju spojevi formule (I) pri čemu R6 je -CONH2;
these heterocycloalkyl, heterocycloalkyl-CH2- and heteroaryl groups being optionally substituted with one or several substituents selected, independently in each instance, from: (C1-C6)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkoxy, heterocycloalkyl, carboxy(C1-C6)alkyl, NR4R5 and OR4; 
navedene heterocikloalkil, heterocikloalkil-CH2- i heteroaril skupine su proizvoljno supstituirane s jednim ili nekoliko supstituenata koji su odabrani, svaki puta neovisno, iz skupa koji čine: (C1-C6)alkil, (C3-C7)cikloalkil, (C1-C6)alkoksi, heterocikloalkil, karboksi(C1-C6)alkil, NR4R5 i OR4;
said alkyl group being optionally substituted with a halogen atom or a (C1-C6)alkoxy, heterocycloalkyl, NH2 or OH group; wherein: and R5 each is, independently of one another, a hydrogen atom, a (C1-C6)alkyl group or a heterocycloalkyl group; 
navedena alkil skupina je proizvoljno supstituirana s atomom halogena ili sa (C1-C6)alkoksi, heterocikloalkil, NH2 ili OH skupinom; pri čemu: i R5 je svaki, međusobno neovisno, vodikov atom, (C1-C6)alkil skupina ili heterocikloalkil skupina;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring; and an NRaRb group, where Ra and Rb are, independently of one another: 
ili osim toga R4 i R5 zajedno tvore, s dušikovim atomom koji ih nosi, 4- do 7-člani prsten; i skupine NRaRb, gdje Ra i Rb su, međusobno neovisno: . vodikov atom;
in the presence of an organic or inorganic base in a polar aprotic solvent. 
u prisutnosti organske ili anorganske baze u polarnom aprotičnom otapalu.
said alkyl group being optionally substituted with a halogen atom or a (C1-C6)alkoxy, heterocycloalkyl, NH2 or OH group; and wherein: and R5 each is, independently of one another, a hydrogen atom, a (C1-C6)alkyl group or a heterocycloalkyl group; or else R4 and R5 together form, with the nitrogen atom which bears them, a 4-to 7-membered ring; and 
navedena alkil skupina je proizvoljno supstituirana s atomom halogena ili s (C1-C6)alkoksi, heterocikloalkil, NH2 ili OH skupinom; i pri čemu: i R5 je svaki, međusobno neovisno, vodikov atom, (C1-C6)alkil skupina ili heterocikloalkil skupina; ili osim toga R4 i R5 zajedno tvore, s dušikovim atomom koji ih nosi, 4- do 7-člani prsten; i
a heterocycloalkyl group, said heterocycloalkyl group being optionally substituted with a (C1-C6)alkyl group; or . 
heterocikloalkil skupina, navedena heterocikloalkil skupina je proizvoljno supstituirana sa (C1-C6)alkil skupinom; ili .
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring; and 
ili osim toga R4 i R5 zajedno tvore, s dušikovim atomom koji ih nosi, 4- do 7-člani prsten; i
R'4 is a hydrogen atom or a (C1-C6)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group; is a halo(C1-C6)alkyl group; 
pri čemu: R'4 je vodikov atom ili (C1-C6)alkil ili aril skupina, navedene alkil i aril skupine su proizvoljno supstituirane s atomom halogena ili NH2 ili OH skupinom; je halo(C1-C6)alkil skupina;
A compound of formula (XIV): wherein: Ra and Rβ are, independently of one another, a hydrogen atom or a (C1-C6)alkyl group or together form, with the carbon atom which bears them, a 3- to 5-membered carbocycle; 
Spoj s formulom (XIV): [image] naznačen time da: Ra i Rβ su, međusobno neovisno, vodikov atom ili (C1-C6)alkil skupina ili zajedno tvore, s ugljikovim atomom koji ih nosi, 3- do 5-člani karbocikal;
A pharmaceutical composition, comprising a compound according to any one of Claims 1 to 12, or a pharmaceutically acceptable salt thereof, and also at least one pharmaceutically acceptable excipient. 
Farmaceutski pripravak, naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1 do 12, ili njegova farmaceutski prihvatljiva sol, te također barem jedno farmaceutski prihvatljivo pomoćno sredstvo.
The (S)-enantiomer of claim 1, or a pharmaceutically acceptable solvate thereof for use in treating a disease or a condition in a mammal selected from the group consisting of pain, depression, cardiovascular diseases, respiratory diseases, psychiatric diseases, neurological diseases and seizures, and combinations thereof. 
(S)-Enantiomer u skladu s patentnim zahtjevom 1, ili njegov farmaceutski prihvatljiv solvat, naznačen time što je namijenjen upotrebi u liječenju bolesti ili stanja kod sisavca koje se bira iz skupine koju čine bol, depresija, kardiovaskularnane bolesti, respiratorne bolesti, psihijatrijske bolesti, neurološke bolesti i napadaji, te njihove kombinacije.
The (S)-enantiomer of claim 1, or a pharmaceutically acceptable solvate thereof for use in treating a disease or condition in a mammal by the inhibition of ion flux through a voltage-gated sodium channel in the mammal. 
(S)-Enantiomer u skladu s patentnim zahtjevom 1, ili njegov farmaceutski prihvatljiv solvat, naznačen time što je namijenjen upotrebi u liječenju bolesti ili stanja kod sisavca inhibiranjem struje iona kroz naponski natrijski kanal kod sisavca.
The (S)-enantiomer of claim 1, or a pharmaceutically acceptable solvate thereof for use in decreasing ion flux through a voltage-gated sodium channel in a cell in a mammal. 
(S)-Enantiomer u skladu s patentnim zahtjevom 1, ili njegov farmaceutski prihvatljiv solvat, naznačen time što je namijenjen upotrebi u slabljenju struje iona kroz naponski natrijski kanal u stanici kod sisavca.
The use of the (S)-enantiomer of claim 1 in the preparation of a medicament for the treatment of a disease or condition ameliorated or alleviated by the inhibition of a voltage-gated sodium channel in mammal. 
Upotreba (S)-enantiomera u skladu s patentnim zahtjevom 1 u pripravi medikamenta za liječenje bolesti ili stanja koja se ublažuju ili olakšavaju inhibiranjem naponskog natrijskog kanala kod sisavca.
A method of producing fertilizer out of sludge, in which method sludge is heated with superheated steam for achieving hygienization to destroy pathogenic microorganisms, characterized by the sludge being heated to a temperature of 60 to 100 °C with superheated steam, which is a gas mixture out of water vapour and combustion gas of a fuel, the superheated steam having a temperature of 200 to 600 °C to activate increasing of the amount of soluble carbon in the sludge and to restart biodegradation of the sludge by using non-pathogenic microorganisms still remaining in the sludge after the heating, the treatment with superheated steam being performed in normal atmospheric pressure in an unpressurized steam treatment unit, and the treatment with superheated steam being performed as a continuous-type process instead of a closed batch-type process. 
Metoda za proizvodnju gnojiva iz mulja, u ovoj se metodi mulj zagrijava superzagrijanom parom zbog postizanja higijenizacije u svrhu uništavanja patogenih mikroorganizama, karakterizirana zagrijavanjem mulja do temperature 60 do 100°C superzagrijanom parom, koja je plinovita smjesa vodene pare i plina izgaranja goriva, superzagrijana para ima temperaturu od 200 do 600°C kako bi aktivirala povećanje količine topljivog ugljika u mulju i kako bi ponovo pokrenula biorazgradnju mulja koristeći nepatogene mikroorganizme još preostale u mulju nakon zagrijavanja, tretiranje superzagrijanom parom se izvodi pri normalnom atmosferskom tlaku u beztlačnoj jedinici za tretiranje parom i tretiranje superzagrijanom parom se izvodi kao kontinuirani postupak umjesto zatvorenog serijskog postupka.
A method according to claim 1, characterized by the sludge being heated to a temperature of 60 to 90 °C. 
Metoda u skladu s patentnim zahtjevom 1, karakterizirana zagrijavanjem mulja do temperature od 60 do 90°C.
A method according to claim 1 or 2, characterized by the sludge being treated with superheated steam for 20 to 60 minutes. 
Metoda u skladu s patentnim zahtjevom 1 ili 2, karakterizirana tretiranjem mulja superzagrijanom parom tijekom 20 do 60 minuta.
A method according to claim 3, characterized by the sludge being treated with superheated steam for 20 to 30 minutes. 
Metoda u skladu s patentnim zahtjevom 3, karakterizirana tretiranjem mulja superzagrijanom parom tijekom 20 do 30 minuta.
A method according to claim 5, characterized by monitoring and controlling the moisture of the sludge during the treatment with superheated steam in such a way that the moisture of the material changes in the treatment by +/-2 % at most to prevent substantial drying of the sludge. 
Metoda u skladu s patentnim zahtjevom 5, karakterizirana praćenjem i nadziranjem vlažnosti mulja za vrijeme tretiranja superzagrijanom parom na način da se vlažnost materijala tijekom tretiranja mijenja najviše ±2% zbog sprječavanja sadržajnog isušivanja mulja.
A method according to any one of the preceding claims 1 to 7, characterized by minimizing the evaporation of nitrogen-containing ammonia or another nitrogen compound generated by the sludge by maintaining a moisture level and/or a temperature during the treatment with superheated steam. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva 1 do 7, karakterizirana minimaliziranjem isparavanja amonijaka koji sadrži dušik ili drugih dušikovih tvari nastalih iz mulja održavanjem razine vlažnosti i/ili temperature za vrijeme tretiranja superzagrijanom parom.
purification plant sludge. 
mulj iz postrojenja za pročišćavanje.
A method according to any one of the preceding claims 1 to 11, characterized by the sludge treatment with superheated steam being performed with a steam-treatment apparatus which comprises at least one steam-treatment unit arranged to use superheated steam and into which the material to be treated is brought. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva 1 do 11, karakterizirana tretiranjem mulja superzagrijanom parom koje se izvodi u uređaju za tretiranje parom koji sadrži barem jednu jedinicu za tretiranje parom postavljenu za korištenje superzagrijane pare i u koju se unosi material koji treba tretirati.
A method according to any one of the preceding claims 1 to 12, characterized by performing the method with a steam-treatment apparatus comprising a first and a second steam-treatment unit arranged to use superheated steam, and by transferring the material treated in the first steam-treatment unit into the second steam-treatment unit. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva 1 do 12, karakterizirana izvođenjem metode s uređajem za tretiranje parom koja obuhvaća prvu i drugu jedinicu za tretiranje parom postavljene za uporabu superzagrijane pare, i prijenosom materijala tretiranog u prvoj jedinici za tretiranje parom u drugu jedinicu za tretiranje parom.
A method according to claim 12, characterized by bringing sludge to the treatment during the treatment with superheated steam in a continuous-type process, and removing sludge from the treatment with superheated steam. 
Metoda u skladu s patentnim zahtjevom 12, karakterizirana donošenjem mulja na tretiranje za vrijeme tretiranja superzagrijanom parom u kontinuiranom postupku, i uklanjanje mulja iz postupka tretiranja superzagrijanom parom.
A method according to any one of the preceding claims 1 to 14, characterized by monitoring, after the treatment with superheated steam during bioredegradation of the sludge, the maturity degree of the biodegradation of the sludge. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva 1 do 14, karakterizirana praćenjem stupnja zrelosti mulja nakon tretiranja superzagrijanom parom za vrijeme biodegradacije mulja.
A method according to claim 15, characterized by monitoring the maturity degree of the bioredegradation of the sludge by measuring gas emissions of the sludge. 
Metoda u skladu s patentnim zahtjevom 15, karakterizirana praćenjem stupnja zrelosti biodegradacije mulja mjerenjem emisije plinova iz mulja.
A method according to claim 15, characterized by monitoring the maturity degree of the bioredegradation of the sludge by measuring carbondioxide emissions of the sludge. 
Metoda u skladu s patentnim zahtjevom 15, karakterizirana praćenjem stupnja zrelosti biodegradacije mulja mjerenjem emisije ugljikovog dioksida iz mulja.
The derivative according to claim 1, wherein R1-R10 is selected from the group consisting of SEQ ID NO: 10-20. 
Derivat u skladu s patentnim zahtjevom 1, pri čemu je R1-R10 odabran iz grupe koja se sastoji od SEQ ID NO: 10-20.
The use according to claim 18, wherein said bacteria are selected from the group consisting of: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Citrobacter freundii,, Pseudomonas aeruginosa, and Acinetobacter baumannii. 
Uporaba u skladu s patentnim zahtjevom 18, pri čemu su navedene bakterije odabrane iz grupe koja se sastoji od: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Citrobacter freundii, Pseudomonas aeruginosa i Acinetobacter baumannii.
A process for preparing a polymyxin derivative of formula (I) as defined in claim 1 comprising modifying a natural or synthetic polymyxin or octapeptin compound or a derivative thereof having 4 to 6 positively charged residues by replacing 1 to 4 of said residues by neutral residues, or by a covalent bond, or converting 1 to 4 of said residues into neutral residues in order to obtain a polymyxin derivative of formula (I) according to claim 1, having 2 or 3 positively charged residues. 
Postupak za pripravu derivata polimiksina formule (I) kako je definirano u patentnom zahtjevu 1 obuhvaća modificiranje prirodnog ili sintetskog polimiksina ili tvari oktapeptina ili njihovih derivata koji imaju 4 do 6 pozitivno nabijenih ostataka zamjenom 1 do 4 navedenih ostataka neutralnim ostacima, ili kovalentnim vezanjem, ili pretvorbom 1 do 4 navedenih ostataka u neutralne ostatke zbog dobivanja derivata polimiksina formule (I) u skladu s patentnim zahtjevom 1, koji ima 2 do 3 pozitivno nabijena ostatka.
The process according to claim 23 comprising carrying out the cleavage in step a) using a combination of both chemical and enzymatic treatments. 
Postupak u skladu s patentnim zahtjevom 23 obuhvaća provođenje cijepanja u koraku a) koristeći kombinaciju i kemijskog i enzimskog tretiranja.
The compound for use of Claim 1, wherein the disease or a condition is selected from pain, depression, cardiovascular diseases, respiratory diseases, psychiatric diseases, neurological diseases and seizures, and combinations thereof. 
(S)-Enantiomer u skladu s patentnim zahtjevom 1, ili njegov farmaceutski prihvatljiv solvat, naznačen time što je namijenjen upotrebi u liječenju bolesti ili stanja kod sisavca koje se bira iz skupine koju čine bol, depresija, kardiovaskularnane bolesti, respiratorne bolesti, psihijatrijske bolesti, neurološke bolesti i napadaji, te njihove kombinacije.
is an amino acid residue selected from the group consisting of lysine (K), arginine (R), alanine (A) and histidine (H), 
je aminokiselinski ostatak odabran iz skupine koju čine lizin (K), arginin (R), alanin (A) i histidin (H),
is an amino acid residue selected from the group consisting of alanine (A) and tyrosine (Y), 
je aminokiselinski ostatak odabran iz skupine koju čine alanin (A) i tirozin (Y),
is any amino acid residue, n and m, independently, are 0 or an integer of more than 0, and wherein the amino acid sequence according to Formula I is not identical with, or does not comprise the 7-mer polypeptide fragment of alpha-synuclein having the amino acid sequence KNEEGAP, said at least one peptide or polypeptide having a binding capacity to an antibody which is specific for an epitope of alpha-synuclein comprising the amino acid sequence KNEEGAP for use in preventing and/or treating synucleinopathies. 
je bilo koji aminokiselinski ostatak, n i m su međusobno neovisno 0 ili neki cijeli broj veći od 0, i čime aminokiselinska sekvenca prema formuli I nije identična sa sedmomernim fragmentom polipeptida od alfa-sinukleina koji ima aminokiselinsku sekvencu KNEEGAP, ili ga ne sadrži, gdje navedeni najmanje jedan peptid ili polipeptid ima kapacitet za vezanje na protutijelo specifično za epitop od alfa-sinukleina koji ima aminokiselinsku sekvencu KNEEGAP, te time, da je za uporabu u prevenciji i/ili liječenju sinukleinopatija.
Composition for the use according to claim 1, wherein X2 is an amino acid residue selected from the group consisting of lysine (K) and arginine (R) and/or X6 is alanine (A). 
Sastav za uporabu prema zahtjevu 1, naznačen time, da X2 je aminokiselinski ostatak odabran iz skupine koju čine lizin (K) i arginin (R) i/ili X6 je alanin (A).
Composition for the use according to any one of claims 1 to 3, characterised in that n and/or m are 1 and X1 and/or X7 are cysteine (C). 
Sastav za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da n i/ili m su 1, a X1 i/ili X7 su cistein (C).
Composition for the use according to any one of claims 1 to 9, characterised in that the at least one peptide or polypeptide is contained in an amount of from 0.1 ng to 10 mg, preferably 10 ng to 1 mg, in particular 100 ng to 100 µg. 
Sastav za uporabu prema bilo kojem od zahtjeva 1 do 9, naznačen time, da se najmanje jedan peptid ili polipeptid nalazi u sastavu u količini od 0,1 ng do 10 mg, poželjno od 10 ng do 1 mg, posebno od 100 ng do 100 μg.
Peptide according to claim 11, characterised in that the peptide is coupled to a pharmaceutically acceptable carrier, preferably KLH (Keyhole Limpet Hemocyanin). 
Peptid prema zahtjevu 11, naznačen time, da je peptid spojen na farmaceutski prihvatljiv nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).
Apparatus (1) according to claim 1 or 2, wherein said moving system (2) comprises a couple of conveyor belts adapted to carry between them one or more of said panels (P) while exercising a compacting pressure. 
Uređaj (1) prema zahtjevu 1 ili 2, naznačen time da navedeni pokretni sustav (2) sadrži par transportnih traka prilagođenih za prenošenje između njih jedne ili više navedenih ploča (P) uz primjenjivanje pritiska sabijanja.